Valiant Organics Ltd(VALIANTORG)

NSE: VALIANTORGBSE: 540145

₹ 437.2+5.92%refreshed 26 Oct, 03:30 pm ISTMarket cap: ₹ 1,226 crWebsite: www.valiantorganics.comUpdated: 24 Oct 2026

About

Valiant Organics is a Mumbai-headquartered speciality chemicals maker founded in 1984 and part of the Aarti Group. Its chemistries include chlorination, hydrogenation, ammonolysis, acetylation, sulphonation and methoxylation. It runs 6 manufacturing units across 5 locations with total production capacity above 80,000 TPA, and it reported FY26 revenue of Rs 738.76 Cr. The company says it is the only domestic producer of chlorophenols and a leading global manufacturer in that product family.^[1][2]

Business segments

Speciality Chemical Division: revenue of Rs 574.82 Cr in FY26, or 77.8% of the total.^[3][1]
Pharma Division: revenue of Rs 163.94 Cr in FY26, or 22.2% of the total.^[3][1]
In FY25 the company reported a single Chemicals segment, split Rs 682.27 Cr within India and Rs 36.49 Cr outside India.^[4]

Revenue by chemistry

FY26 revenue by chemistry: hydrogenation 48%, ammonolysis 26%, chlorination 20%, others 6%.^[1][5]
In Q1 FY27, hydrogenation was 54% of revenue (48% in FY26), ammonolysis 21% (26% in FY26) and chlorination 19%.^[6]
FY26 volume shares: hydrogenation 38%, ammonolysis 33%, chlorination 27%.^[5]

Products and market position

The company says it is the only domestic producer of chlorophenols and a leading global manufacturer in that product family.^[1]
It says it is one of the few commercial players in Ortho Anisidine and Para Anisidine, and one of the largest domestic manufacturers of PAP and PNA.^[1]
Certifications as of FY26: OHSAS 18001:2007, ISO 14001:2015 and ISO 9001:2015.^[1]

Plants and capacity

As of FY26 it runs 6 manufacturing units across 5 locations, with total production capacity above 80,000 TPA, up from 70,000 TPA in FY25.^[1][4]
Sarigam chlorination plant: 21,600 MTPA (up from 18,000 MTPA), making PCP, OCP, DCP and TCP.^[1][6]
Jhagadia Unit 1 (hydrogenation and methoxylation): 28,800 MTPA, making ONA/OA, PNA/PA and IPPCA.^[1]
Jhagadia Unit 2 (hydrolysis and hydrogenation): 12,000 MTPA, making PAP and pharma intermediates.^[1]
Ahmedabad (acetylation, sulphonation and methoxylation): 1,800 MTPA.^[1]
Capital work in progress fell from INR 657 Mn at FY25 to INR 86 Mn at H1 FY26, which points to new assets being commissioned.^[7]

Key operating numbers

Gross margin was 43% in Q1 FY27, up from 39% a year earlier.^[6]
Raw material cost was 57% of sales in Q1 FY27, down from 61% a year earlier.^[6]
Gross margin was 46% in Q2 FY26, compared with 36% in Q2 FY25. The company credited better raw-material efficiency and product mix.^[7]
R&D spend was about Rs 53 lakh in FY26, compared with about Rs 6 lakh in FY25.^[1]

Customers, markets and raw materials

Revenue was 95% domestic and 5% exports in FY26, compared with 94% domestic and 6% exports in FY25.^[1][4]
The company has an export presence in Asia, Europe and the USA.^[1]
As part of the Aarti Group, it sources key raw materials such as PNCB from Aarti Industries.^[1]

Investments and associates

On April 24, 2025, it agreed to subscribe to 26.25% of a renewable power SPV, Pro-Zeal Green Power Eight, including CCDs.^[4]
It made an additional capital contribution of Rs 9.43 crore to an LLP on June 16, 2025.^[1]
Share of profit from associates was INR 72 Mn in Q1 FY27, compared with INR 6 Mn a year earlier.^[6]

Recent developments

On August 05, 2026, CRISIL reaffirmed the company's A- long-term rating and revised the outlook from Negative to Stable.^[1]
Q1 FY27 revenue was the highest quarterly revenue in six quarters, after a trough in H1 FY26.^[6]

Market Cap

₹1,226 Cr

High / Low

₹508 / 195

Stock P/E

21.3

Price / Book

1.5

Book Value

₹271

EPS

₹11.9

No. of Shares

2.8 Cr

ROCE

5.4%

ROE

4.5%

OPM

7.4%

Debt / Equity

0.33

Sales

₹739 Cr

Net Profit

₹33 Cr

Promoter holding

37.9%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Walk the talk
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.
Concall briefs
Quarter-by-quarter earnings-call briefs - what changed and why.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials

Valiant Organics Ltd(VALIANTORG)

About

Business segments

Revenue by chemistry

Products and market position

Plants and capacity

Key operating numbers

Customers, markets and raw materials

Investments and associates

Recent developments

Signal history

The analysis Screener can't give you

AI Deep Dive

Verdict

Company data

Product Segments

Corporate Actions